Seeking Alpha

More on Abbott Laboratories' (ABT) Q1: Segment revenue gains led by Proprietary Pharmaceuticals...

More on Abbott Laboratories' (ABT) Q1: Segment revenue gains led by Proprietary Pharmaceuticals (+6.6%), Nutritionals (+11%), and Core Laboratory Diagnostics (+12.8%). Says it's on track to separate into two companies by year end. Raises its outlook for full-year 2012 EPS to $5.00-$5.10, from prior guidance of $4.95-$5.05. Shares +1.3% premarket. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)